CRYOABLATION
FREEZING CANCER WITH PRECISION

Cryoablation uses the Joule-Thomson effect: high-pressure argon gas (3,000-4,000 psi) rapidly expands through a small orifice at the cryoprobe tip, dropping the temperature to -40 to -160 degrees C in seconds. This freezes surrounding tissue into a visible ice ball that expands through the tumour.

“Unlike RFA and MWA where the ablation zone is invisible and inferred from temperature assumptions, the cryoablation ice ball is directly visible on CT in real time — the most important clinical advantage of the technique.”

• How Freezing Kills Tumour Cells

  Cell death from freezing occurs through multiple mechanisms: ice crystal formation disrupts cell membranes; osmotic dehydration as extracellular ice formation draws water out of cells; vascular stasis from ice crystal formation in tumour microvasculature; and immunogenic cell death that activates anti-tumour immune responses.

• The Visible Ice Ball: Key Clinical Advantage

  The ice ball appears as a hypodense region on CT and signal void on MRI — visible in real time during the procedure. The interventional radiologist monitors the ice ball boundary to ensure it extends 5-10 mm beyond the tumour margin. This real-time margin control is unique to cryoablation and is why it is preferred near critical structures.

• Argon and Helium: Freeze and Thaw

  Argon gas creates the freeze phase. Helium gas has the opposite Joule-Thomson effect — it warms when expanded — and is used to actively thaw the ice ball. A complete freeze-thaw-freeze cycle (two full freeze cycles with an active thaw between) maximises cell death and is standard for most cryoablation protocols.

• Cryoimmunotherapy: The Abscopal Potential

  Cryoablation causes immunogenic cell death — releasing tumour antigens and damage-associated molecular patterns (DAMPs) that activate dendritic cells and T-cells. Combination with checkpoint inhibitors (anti-PD-1/PD-L1) may amplify the abscopal effect — a systemic anti-tumour response beyond the ablation site — under active clinical investigation.

Cryoablation is specifically preferred over thermal ablation in situations where real-time margin control and avoidance of thermal spread to adjacent structures is critical.

• Renal Cell Carcinoma (Best-Evidenced Indication)

  Percutaneous cryoablation for T1a RCC (less than 4 cm) is guideline-accepted with 5-year recurrence-free survival comparable to partial nephrectomy. Preferred over RFA and MWA for central tumours adjacent to the collecting system — where heat-based ablation risks urinoma formation — and for posterior renal tumours where the ice ball boundary can be monitored to avoid collecting system injury.

• Prostate Cancer: Whole-Gland and Focal Cryoablation

  Primary whole-gland cryoablation is an established treatment for localised prostate cancer, particularly in patients who decline or are unsuitable for surgery or radiation. Focal cryoablation (treating only the dominant cancer focus) is increasingly used for low-intermediate risk prostate cancer to preserve urinary and erectile function. Real-time transrectal ultrasound monitoring guides ice ball formation.

• Bone Metastases: Pain Palliation and Local Control

  CT-guided cryoablation for painful bone metastases achieves superior pain control compared to radiation therapy alone in prospective trials. The visible ice ball allows precise treatment of the painful lesion while monitoring ice ball extension to protect adjacent neural structures — critical for spinal and pelvic metastases near nerve roots.

• Liver Tumours and Lung Lesions

  Cryoablation for HCC and colorectal liver metastases is used at specialist centres, particularly for subcapsular tumours where thermal ablation risks capsular injury and peritoneal seeding, and for tumours adjacent to the bile duct where heat-based ablation risks biliary stricture. For lung, cryoablation is used for ground-glass lesions and small peripheral NSCLC.

• -160 CMinimum temperature at cryoprobe tipAchieved via Joule-Thomson expansion of argon gas — far below the -40 degrees C threshold for instant cell death.
• 90%+5-year recurrence-free survival for T1a RCC with cryoablationComparable to partial nephrectomy — with preservation of renal function and no surgical incision.
• 2Freeze-thaw cycles per cryoablation session (standard protocol)Two full freeze cycles with active helium thaw between maximises tumour cell death.
• 5-10 mmRequired ice ball margin beyond tumour edgeReal-time CT monitoring ensures the ice ball extends adequately beyond the tumour to prevent incomplete ablation.
• 94–100%Technical success rate in renal cryoablation seriesModern percutaneous renal cryoablation studies report very high technical success, showing that the tumour can usually be fully targeted and treated in a single planned session.
• 4.5%Major complication rate in a large percutaneous renal cryoablation seriesThis supports the minimally invasive safety profile of cryoablation, especially when compared with more invasive surgical approaches in selected patients.

Specialist cryoablation programmes at leading centres — with particular expertise in renal, prostate, and bone indications.

1. 1

   Case Review and Eligibility

   Review of imaging, histology, and clinical history to confirm cryoablation eligibility — including tumour size, location relative to critical structures, and whether cryoablation offers advantage over thermal ablation for the specific case.

2. 2

   Centre Matching

   Peking University Cancer Hospital and Zhongshan Hospital Shanghai for liver and renal cryoablation. Specialist urological centres for prostate cryoablation. Interventional radiology teams with dedicated bone metastasis cryoablation experience for pain palliation cases.

3. 3

   Remote Pre-Procedure Review

   Interventional radiologist review of imaging before travel — confirming technique (number of probes, needle trajectory, monitoring plan) and providing preliminary assessment of expected ice ball coverage.

4. 4

   Travel and Procedure Logistics

   Cryoablation is typically a same-day or overnight admission. Multiple probes may be required for larger tumours. CancerFax arranges all logistics including medical visa, accommodation, and post-procedure monitoring support.

5. 5

   Follow-Up and Response Assessment

   CT or MRI at 4-6 weeks post-cryoablation assesses the ablation zone. CancerFax coordinates remote imaging review and advises on need for repeat ablation or complementary treatment.

Each page covers one cryoablation topic in depth.

Frequently Asked Questions